Calton & Associates, Inc. Exelixis, Inc. Transaction History

Calton & Associates, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 12, 2022	SELL	$17.44 - $23.16 $159,349 - $211,612	-9,137 Closed	0 $0
Q1 2022 Apr 12, 2022	BUY	$17.03 - $22.67 $155,603 - $207,135	9,137 New	9,137 $207,000
Q4 2020 Jan 25, 2021	SELL	$18.39 - $24.8 $151,478 - $204,277	-8,237 Closed	0 $0
Q3 2020 Oct 30, 2020	SELL	$20.67 - $26.94 $4,857 - $6,330	-235 Reduced 2.77%	8,237 $201,000
Q2 2020 Aug 10, 2020	BUY	$16.46 - $27.42 $139,449 - $232,302	8,472 New	8,472 $201,000

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Calton & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Calton & Associates, Inc. with notifications on news.